Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00743067 |
This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of oral daily GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.
Condition | Intervention | Phase |
---|---|---|
Solid Tumors |
Drug: GSK1363089 (formerly XL880) |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors |
Estimated Enrollment: | 37 |
Study Start Date: | June 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
GSK Clinical Trial Call Center | |
Boston, Massachusetts, United States, 02115 | |
United States, Michigan | |
GSK Clinical Trial Call Center | |
Detroit, Michigan, United States, 48201 |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Study ID Numbers: | MET111648, XL880-002 |
Study First Received: | August 26, 2008 |
Last Updated: | August 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00743067 |
Health Authority: | United States: Food and Drug Administration |
Solid Tumors GSK1363089 XL880 MET inhibitor c-Met |